MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: other"

  • 2016 International Congress

    Patient satisfaction with flexible botulinum toxin injection intervals – Preliminary results of a telephone survey

    C. Linder, S. Macher, E. Auff, T. Sycha (Vienna, Austria)

    Objective: To evaluate satisfaction with flexible injection intervals in patients receiving Botulinum toxin therapy at our outpatient clinic. Background: Botulinum toxin therapy (BoNT) for muscular…
  • 2016 International Congress

    A crossover study of pretarsal and preseptal injections of botulinum toxin type A (BTX-A) in the treatment of hemifacial spasm and blepharospasm

    A. Choolam, K. Kulkantrakorn, P. Lolekha (Pathumthani, Thailand)

    Objective: To compare the efficacy, patient satisfaction, and side effects between pretarsal and preseptal injection sites on BTX-A treatment in abnormal orbicularis oculi contraction in…
  • 2016 International Congress

    Apraclonidine in the treatment of ptosis

    S. Wijemanne, D. Vijayakumar, J. Jankovic (Houston, TX, USA)

    Objective: To describe the improvement in ptosis with apraclonidine in patients with botulinum toxin (BoNT) induced ptosis. Background: Ptosis is a manifestation of a variety…
  • 2016 International Congress

    Prevalence of hemifacial spasm in Northern Cyprus

    S. Usar Incirli, F. Selcuk, C.M. Akbostanci (Nicosia, Cyprus)

    Objective: To estimate the prevalence and analyze the clinical profile of hemifacial spasm in Northern Cyprus. Background: Hemifacial spasm (HFS) is characterized by involuntary, clonic…
  • 2016 International Congress

    Quality of life and epidemiological profile of patients undergoing botulinum toxin treatment

    G. Amorelli, L.F. Vasconcellos, M. Spitz, L.F. Fraga (Rio de Janeiro, Brazil)

    Objective: To trace a clinical and epidemiological profile of patients treated with botulinum toxin, evaluating the impact on quality of life. Background: The Botulinum Toxin…
  • 2016 International Congress

    Hemifacial spasm – Therapeutic assessment of botulinum toxin

    H.A.G. Teive, J.P. Matisti, A.D. Kleinfelder, N.B. Galli (Curitiba, Brazil)

    Objective: To evaluate the long-term effect of botulinum toxin type A (BTX-A) in the treatment of hemifacial spasm (HFS) in a large group of patients…
  • 2016 International Congress

    Individualized botulinum toxin type A therapy of bilateral upper limb essential tremor by multi-sensor kinematic technology

    O. Samotus, H. Moradi, M. Jog (London, ON, Canada)

    Objective: To demonstrate efficacious and safe reduction in bilateral upper limb tremor severity by serial botulinum toxin type A injection parameters kinematically determined using a…
  • 2016 International Congress

    Botulinum toxin treatment of freezing of gait in Parkinson’s disease patients as reflected in functional magnetic resonance imaging of leg movement

    M. Vaštík, P. Hok, P. Hluštík, P. Kanovský, Z. Tüdös (Olomouc, Czech Republic)

    Objective: To reflect botulinum toxin treatment of freezing of gait in Parkinson´s disease patients in functional magnetic resonance imaging of leg movement. Background: Freezing of…
  • 2016 International Congress

    Efficacy and safety of abobotulinumtoxinA in craniocervical dystonia and hemifacial spasm

    A. Jesic, D. Stefanovic, N. Delibasic, J. Radanov, M. Cvijanovic (Victoria, Seychelles)

    Objective: The aim of this paper was to analyze efficacy and safety of abobotulinumtoxinA (A/Abo), and compare them between the groups of patients with CD…
  • 2016 International Congress

    Multicentre retrospective chart review of patients treated with incobotulinumtoxinA to evaluate sustained efficacy and tolerability in converted and de-novo conditions

    M.S. Jog, R.M. Jog, A. Tewari, D. Hobson, D. Stewart, D. King (London, ON, Canada)

    Objective: This study aimed to determine whether IncobotulinumtoxinA (IBTX) provides sustained efficacy as a treatment modality patients in both de-novo patients and patients converted from…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley